EGRX - Eagle Pharmaceuticals Inc-DE Stock Price, Fair Value and News

$0.340.00 (0.00%)

Market Closed

86/100

EGRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

86/100

EGRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Target 6M

EGRX Stock Valuation Analysis

Valuation

Max Portfolio %

EGRX Price Action

EGRX RSI Chart

EGRX Stock Valuation Analysis

Valuation

Max Portfolio %

EGRX Valuation

EGRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Target 6M

EGRX Fundamentals

EGRX Revenue

EGRX Earnings

EGRX Profitability

EGRX Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	267.0M	257.6M	0	0
2022	246.2M	272.2M	298.2M	316.6M
2021	183.0M	189.2M	179.1M	171.5M
2020	192.1M	177.4M	186.1M	187.8M
2019	216.5M	213.9M	203.7M	195.9M
2018	206.5M	215.7M	204.0M	213.3M
2017	236.7M	245.9M	271.1M	236.7M
2016	59.5M	94.4M	126.5M	189.5M
2015	50.5M	50.7M	53.6M	66.2M
2014	20.2M	20.9M	19.1M	19.2M
2013	6.3M	10.0M	13.7M	17.7M
2012	0	0	2.5M	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Eagle Pharmaceuticals Inc-DE

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

CEO	Mr. Scott L. Tarriff
WEBSITE	eagleus.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers Specialty & Generic
EMPLOYEES	134

Eagle Pharmaceuticals Inc-DE Frequently Asked Questions

EGRX is the stock ticker symbol of Eagle Pharmaceuticals Inc-DE. Every public company that trades on a stock exchange gets a ticker symbol.

86.css-4kraf3{margin:0;font-family:"Roboto","Helvetica","Arial",sans-serif;font-weight:400;font-size:1rem;line-height:1.5;letter-spacing:0.00938em;color:#666;font-size:1.25rem;font-weight:400;}/100

EGRX Price Action

EGRX Stock Valuation Analysis

EGRX Valuation

EGRX Price/Sales (Trailing)

The Good, Bad and Ugly

Price Targets

EGRX Fundamentals

EGRX Revenue

EGRX Earnings

EGRX Profitability

EGRX Investor Care

Revenue & Growth

About Eagle Pharmaceuticals Inc-DE

Eagle Pharmaceuticals Inc-DE Frequently Asked Questions

What is the ticker symbol for Eagle Pharmaceuticals Inc-DE? What does EGRX stand for in stocks?

86/100